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Gastroenteropancreatic neuroendocrine neoplasms exhibit a
unique neoplastic proﬁle that is substantially different to
other epithelial cancers. In the absence of common acti-
vating mutations, deﬁning the cellular toolkit and the nexus/
master regulator genes is vital to understand and clinically
target them.
Gastroenteropancreatic neuroendocrine neoplasms
(GEP-NEN), considered a heterogeneous neoplasia,
exhibit ill-deﬁned pathobiology and protean symptom-
atology and are ubiquitous in location. They are difﬁcult
to diagnose, challenging to manage, and outcome de-
pends on cell type, secretory product, histopathologic
grading, and organ of origin. A morphologic and mo-
lecular genomic review of these lesions highlights tumor
characteristics that can be used clinically, such as
somatostatin-receptor expression, and conﬁrms features
that set them outside the standard neoplasia paradigm.
Their unique pathobiology is useful for developing di-
agnostics using somatostatin-receptor targeted imaging
or uptake of radiolabeled amino acids speciﬁc to
secretory products or metabolism. Therapy has evolved
via targeting of protein kinase B signaling or somato-
statin receptors with drugs or isotopes (peptide-recep-
tor radiotherapy). With DNA sequencing, rarely
identiﬁed activating mutations conﬁrm that tumor
suppressor genes are relevant. Genomic approaches
focusing on cancer-associated genes and signaling
pathways likely will remain uninformative. Their
uniquely dissimilar molecular proﬁles mean individual
tumors are unlikely to be easily or uniformly targeted
by therapeutics currently linked to standard cancer ge-
netic paradigms. The prevalence of menin mutations in
pancreatic NEN and P27KIP1 mutations in small intesti-
nal NEN represents initial steps to identifying a regula-
tory commonality in GEP-NEN. Transcriptional proﬁling
and network-based analyses may deﬁne the cellular
toolkit. Multianalyte diagnostic tools facilitate more ac-
curate molecular pathologic delineations of NEN for
assessing prognosis and identifying strategies for indi-
vidualized patient treatment. GEP-NEN remain unique,
poorly understood entities, and insight into their
pathobiology and molecular mechanisms of growth and
metastasis will help identify the diagnostic and thera-
peutic weaknesses of this neoplasia. (Cell MolGastroenterol Hepatol 2015;1:131–153; http://dx.doi.org/
10.1016/j.jcmgh.2014.12.008)
Keywords: Gastroenteropancreatic Neuroendocrine Neoplasms;
Blood; Carcinoid; Ki-67; Proliferation; Somatostatin; Transcriptome.The Carcinoid Conundrum in Context
Gastroenteropancreatic neuroendocrine neoplasms
(GEP-NEN) are generally considered to be anomalous
neoplasia, given their unusual pathobiology that exhibits
both secretory and proliferative phenotypes. In addition,
they display divergent clinical courses, ranging from indo-
lent to highly aggressive.1 Their protean symptomatology
and ubiquitous sites of origin render them difﬁcult to di-
agnose and vexatious to manage.2 Because they arise from
different organs and diverse neuroendocrine cell types, each
with their own unique transcriptome, the biologic behavior
of these neoplasia is often unpredictable, and their outcome
is variable and uncertain, irrespective of treatment.3
GEP-NEN present a paradox in that they are semantically
grouped as one neoplastic category yet represent numerous
different tumors that share only their neuroendocrine origin
Table 1.Heterogeneity and Diversity in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Tumor
Putative Cell of
Origin Localization Secretory Products Secretory Regulation
Proliferative
Regulation
Omics-Based
Analyses Mutations
Small intestinal
NEN,
“carcinoid”
Enterochromafﬁn
(EC)
Entire GI tract Serotonin, substance P,
guanylin, melatonin
Immune (eg, IL1b), mechanical (eg,
ATP), neural (eg, adrenaline),
somatostatin (PKA, MAPK)
TGFb, EGFR (RAS/
RAF/MAPK, GL1/
SNAIL)
Transcriptome,
LOH, exome,
miRNAome
CDKN1B
Nonfunctional
pancreatic NEN
Precursor (ductal)
cell or
omnipotent stem
cell
Pancreas None deﬁned Calcium dependent Growth factors (eg,
VEGF), PI3K, Akt,
mTOR
Transcriptome,
LOH, exome,
miRNome
MEN-1,
DAXX,
ATRX
Colorectal NEN L, EC Colon-rectum GLP-1, PYY, NPY Nutrient sensinga EC: ATM) EC: Transcriptome,
LOH, exome,
miRNome
—
ECLoma
(type I–III)
Enterochromafﬁn-
like (ECL)
Gastric fundus Histamine Gastrin, muscarinic, vagal
(PI3K/DAG/calcium signaling),
somatostatin
Gastrin, PACAP,
histamine, EGFR
(MAPK)
Transcriptome,
LOH
None (type
II: MEN-
1)
Gastrinoma Gastrin (G) Gastric antrum and
duodenum,
pancreas
Gastrin Environmental (amino acids,
tastants, calcium, pH),
mechanical, vagal (PKA, MAPK,
calcium signaling), somatostatin
IGF-1 Transcriptome,
LOH
MEN-1
CCKoma I Duodenum CCK Environmental (amino and fatty
acids), vagal
— — —
GIPoma K Duodenum, jejunum GIP Nutrient sensinga — — —
Insulinoma Beta Pancreas Insulin GIP, GLP-1, leptin, somatostatin
(depolarization, calcium)
mTOR Transcriptome,
LOH, exome
YY1
Glucagonoma Alpha Pancreas Glucagon GIP, GLP-1, somatostatin
(depolarization, calcium)
— Transcriptome,
LOH
MEN-1
Somatostatinoma Delta Pancreas Somatostatin — Src family kinases,
PI3K-mTOR, MEK
— NF-1
Somatostatinoma Delta (D) Duodenum Somatostatin — Src family kinases,
PI3K-mTOR, MEK
— —
Ghrelinoma Ghrelin (Gr) Entire GI tract Ghrelin b1-adrenergic receptor — — —
PPoma PP Pancreas PP — — — —
VIPoma VIP Entire GI tract
(pancreas, adrenal)
VIP — — — —
Note: Akt, protein kinase B; ATM, ataxia telangiectasia mutated kinase; ATP, adenosine triphosphate; ATRX, alpha thalassemia/mental retardation syndrome X-linked;
CCK, cholecystokinin; DAG, diacylglycerol; DAXX, death-domain associated protein; EC, enterochromafﬁn; EGFR, epidermal growth factor receptor; GI, gastrointestinal;
GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide 1; IGF, insulin-like growth factor; IL, interleukin; LOH, loss of heterozygosity; MAPK, mitogen-activated protein
kinase; MEK, mitogen-activated protein kinase kinase; MEN-1/MEN1, multiple endocrine neoplasia type 1; mTOR, mammalian target of rapamycin; PP, pancreatic
polypeptide; PYY, polypeptide YY (tyrosine, tyrosine); NEN, neuroendocrine neoplasms; NF-1, nuclear factor 1; NPY, neuropeptide Y (tyrosine); PACAP, pituitary adenylate
cyclase-activating polypeptide; PI3K, phosphoinositide-3 kinase; PKA, protein kinase A; PP, pancreatic polypeptide; VEGF, vascular endothelial growth factor; VIP,
vasoactive intestinal peptide; YY1, Yin Yang 1 transcriptional repressor; —, no data.
aSignaling pathways associated with nutrient sensing are poorly characterized.
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March 2015 Decoding the Pathobiology of GEP-NENs 133as a commonality (Table 1). Anatomically, these tumors
arise from a variety of different neuroendocrine cells in
diverse locations throughout the gastroenteropancreatic
system. Functionally, they each produce a variety of different
amine and peptide secretory products, some of which pro-
duce substantial clinical symptomatology or alterations in
metabolic activity. Diverse regulatory systems to modulate
the secretory process exist for the different cell systems.
Proliferation is also different in each system and can range
from indolence to almost completely unregulated growth
with aggressive invasion and diverse metastatic events. A
wide variety of proliferative regulatory systems have been
deﬁned that differ among the cell types and individual tu-
mors. Until recently, the majority of knowledge about the
regulation of secretion and proliferation was descriptive,
with little mechanistic information available. More recently,
the application of sophisticated strategies for exploring the
transcriptome, micro-RNome (miRNome), and exome have
yielded better insights into secretory and proliferative
regulation at a genomic level. Nevertheless, a paucity of in-
formation characterizes our current state of understanding
of these lesions. In particular, there is little appreciation of
the molecular basis by which transformation from a naïve
cell type to a neoplastic phenotype occurs. Resolution of this
issue remains a paramount scientiﬁc concern.
GEP-NEN comprise w1% of all malignancies and
represent the second most common gastrointestinal malig-
nancy after colorectal cancer.4 It has also been accepted that
they are increasing in incidence1,5–7 (estimated annually at
w5%8) and that the majority (95%) are of sporadic
etiology.1 The diagnosis of NEN remains a challenge, given
the often subtle and protean clinical manifestations,9 and
the current understanding of this neoplastic group is
deﬁned more by what is not known (ie, “not typical and/or
unusual” presentation and behavior) rather than what is
known. Tumors of the same organ behave differently. For
example, b-cell pancreatic neoplasms (insulinomas) are
different from G-cell tumors (gastrinomas) of the pancreas
in both symptomatology and malignancy. The former are
invariably benign, and the latter are indubitably malig-
nant.10 The common symptoms are protean and easily
mistaken for other conditions, such as when ﬂushing or
diarrhea are mistaken for symptoms of menopause or irri-
table bowel syndrome, respectively. As a consequence of
tardy recognition of these tumors (the majority are meta-
static when identiﬁed), clinical management is a Sisyphean
task given the advanced nature of the disease and the
paucity of effective therapeutic strategies.9
NEN are heterogeneous whether viewed from a genetic,
biochemical, cellular (proliferation, metastases), organ site,
or symptomatic perspective.11–19 They are difﬁcult to
diagnose and manage, and surgery represents the only
known “cure.”20–22 Standard clinical approaches to monitor
treatment responses are inadequate (limited biomarker
spectrum) and relatively insensitive (limited image
discriminant index).23 Radiological Response Evaluation
Criteria In Solid Tumors v1.1 (RECIST) criteria are insensi-
tive for measuring treatment responses in these often
“indolent” lesions.24 Response to therapies is rarelyassociated with early measurable (detectable) changes in
tumor size and represents a substantial limitation in GEP-
NEN management.25,26
The recognition of somatostatin receptors as key reg-
ulators of NEN function provided an effective therapeutic
strategy in terms of secretory inhibition, symptomatic
control, and quality of life improvement.27 The impact of
such agents (somatostatin analogs) on the proliferative
regulation of NEN has also been clinically demonstrated as
having some degree of efﬁcacy.28,29 Other agents (ever-
olimus, sunitinib, bevacizumab, geﬁtinib) euphemistically
considered as targeting speciﬁc proliferative pathways
in NEN have proved of relatively modest beneﬁt given
their marginal efﬁcacy and substantial adverse-event
proﬁle.30–34 A critical shortcoming in the latter strategy
is the inability to identify before treatment whether the
“target” exists.
Overall, the lack of effective agents represents the
limited understanding of the biologic basis of NEN and the
paucity of information as to the molecular nature of the
disease.35 This disappointing situation has arisen for two
reasons. First, the limited ﬁnancial investment in exploring a
disease therapy reﬂects its perceived low incidence and
health-care impact on the population. Second, NEN disease
in itself presents a formidable investigative problem. Indi-
vidual neoplasms arise from a plethora of different cell
types (albeit with a common neuroendocrine element) and
organs systems. They exhibit different regulatory systems,
and their rarity has inhibited the acquisition of large spec-
imen samples needed for identiﬁcation of molecular mech-
anisms. The fact that they arise from the diffuse
neuroendocrine system, which itself is poorly characterized
and little understood, has compounded the investigative
problem.36
The scientiﬁc conundrum of these neoplasms is further
ampliﬁed by the diverse observations with respect to their
differences from other forms of cancer in epidemiology,
biology, and behavior. Typically, the incidence rates of
cancer are nonlinear, and not all multicellular organisms
develop neoplasia. This disconnect between body mass
(which is a surrogate for cell number) and cancer incidence
is known as Peto’s paradox37; this identiﬁes that natural
selection favors against carcinogenesis. NEN, however, do
not conform to the declining acceleration model of cancer
development evident in the majority of neoplasia.38 Instead,
these neoplasms tend to occur later than other cancers
(usually >60 years of age) and continue increasing in inci-
dence with age (risk as high as 7 out of 100,000 in the
seventh decade).1,8 Indeed, the frequency of these neo-
plasms has been reported to be as high as 1% in the pop-
ulation (at autopsy).39 Such a high prevalence is more
consistent with timed exposure per Peto’s experiments than
to any paradox. It is also evident that the proportion of
neuroendocrine cells in the body—which is estimated at
w1% 40—closely mirrors the proportion of cancers that
develop with neuroendocrine features (1%). Thus, it seems
likely that this class of neoplasms (neuroendocrine) may not
be regulated by the same rules that govern the development
of more common cancers and that it represents a different
134 Kidd et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 2neoplastic phenomenon compared with the classic “hit
theory” mutation-driven oncologic paradigm.
In this appraisal of the state of neuroendocrine
neoplasia, we seek to examine the unique nature of NEN and
scrutinize the evidence indicating their differences from the
accepted cancer model. The goal is to elucidate whether
NEN disease is actually different from other cancers or
whether this is simply a presumption that has evolved out of
misinterpretation of available data, a paucity of information,
or an example of oncologic dialetheism.41 Our thesis is that
molecular advances are necessary to advance the under-
standing of the disease and that, in particular, the devel-
opment of a molecular toolkit for these neoplasms will
prove to be the appropriate pathway to the development of
effective diagnosis and therapy.Functional Cellular Morphology
The term “neuroendocrine” is a composite description of
a cell that exhibits mixed morphologic and physiologic at-
tributes of the neural and endocrine regulatory systems. The
bicameral cell includes a neural cell phenotype expressing
proteins that include neuron-speciﬁc enolase, synaptophy-
sin, chromogranin A (CgA), and neuronal ﬁlament proteins
such as internexin a. In addition, they express a physiologic
“hormone” phenotype classically ascribed to endocrine
cells.42
Structurally, neuroendocrine cells can either be “open”
or “closed” to the lumen. Most intestinal enterochromafﬁn
(EC) and D (somatostatin) cells and gastric G (gastrin) cells
are of the open type, with apical cytoplasmic extensions that
project into the glandular lumen with short microvilli and
allow the cell to sense physical or chemical variations in
luminal content.43 The neuronal component is represented
at the basal aspect of the cells by often extensive and
elongated axon-like cytoplasmic processes that abut adja-
cent cells.44 Multiple processes, which can extend up to
50–80 mm in length, often possess a terminus resembling a
synaptic-like bouton that likely interacts with adjacent non-
neuroendocrine cells.45 These dendritic-like processes
embody the neuronal component of the neuroendocrine cell
whereby signal substances are delivered in direct proximity
to other coexistent neural ﬁlaments in the lamina propria or
contiguous mucosal cells and the immune cells.46
Closed cells include the majority of fundic neuroendo-
crine cells, the enterochromafﬁn-like (ECL) cell as well as
the gastric D, EC, and X/A-like (ghrelin) cells. Such cells
do not access the lumen but are regulated by basal neural
and hormonal signals. Like open cells, however, they
also exhibit long, axon-like processes that regulate the
function of other cell types.47 Tumor cells, similar to
normal neuroendocrine cells, exhibit almost all the
morphologic characteristics of neural and endocrine cell
types, including secretory machinery as well as axonal
structures such as internexin a expression.48 Assessment
of the secretory proﬁle provides the basis for the much-
used clinical measurements of, for example, the granin
family or amines such as 5-hydroxytryptamine (5-HT, se-
rotonin).49 However, the pathobiologic relevance of theirneural characteristics remains largely uninvestigated. It is
likely that tumor cells both directly sense and “taste” the
lumen,43,50 transduce these messages (albeit in an uncon-
trolled, paroxysmal fashion), and modulate the behavior of
mucosal cells such as inﬂammatory cells or cells involved
in the regulation of nociception and motility. These local
events and the systemic secretory products provide the
basis for the clinical features (such as pain and diarrhea)
evident in some GEP-NEN.1Mechanistic Secretory Matrix
At least 17 individual neuroendocrine cell types have
been identiﬁed within the gastrointestinal tract and
pancreas, reﬂecting the plethora of bioactive amines and
peptides they synthesize and secrete (Figure 1). Secretory
products are stored in large dense-core vesicles or in small
synaptic-like vesicles.51 Large dense-core vesicles bud
from the trans-Golgi network (TGN) where prohormones
and proneuropeptides are processed and stored. Although
some granules store individual peptide hormones, several
different peptides or amines may be colocalized.52,53 CgA
is a key constitutive protein involved in the biogenesis
of dense-core secretory granules at the level of the
TGN. Amines are accumulated in secretory vesicles via
type I vesicular monoamine transporters (VMAT1 in EC
cells, VMAT2 in ECL cells) and may be colocalized in large
dense-core vesicles or processed into small synaptic-like
vesicles.
The process of neuroendocrine cell secretion is best
exempliﬁed by CgA,54 which (often with CgB) initially ac-
cumulates in the TGN before incorporation into immature
secretory vesicles (ISG). In the ISG, chromogranins bind to
low-afﬁnity vesicle membrane receptors, initiating the
sorting of other ISG proteins to the regulated secretory
pathway (Figure 2). Further development of ISG into mature
secretory granules involves calcium (Ca2þ) inﬂux, granule
acidiﬁcation, prohormone processing (including chromog-
ranins themselves), and the uptake of amines (eg, 5-HT).
Thereafter, after receptor-mediated Ca2þ inﬂux, matured
granules dock at the cell membrane via expression of syn-
taxin, synaptotagmin, vesicle-associated membrane protein
2 (VAMP2), and synaptosomal-associated protein, 25-kDa
(SNAP25) with release of their contents into the extracel-
lular milieu.55
Tumor cells, like their normal counterparts, synthesize
and secrete a similar diverse array of bioactive products.
However, processing in neoplastic cells differs from not only
normal cells but between individual tumor cell types. Thus,
CgA processing varies between different neuroendocrine
tissues such that there is more extensive cleavage in
pancreatic islets than in the adrenals, and different fragment
proﬁles exist for each of the pancreatic a, b, D, and
pancreatic polypeptide cells.56 This differential processing
has implications for the accurate biochemical measurements
of secretory product.57 Of biologic relevance, however, is
that the smaller biologically active peptides (eg, vasostatin I
and II, or chromostatin)58,59 differentially regulate tumor
cell proliferation and metastasis.60
Figure 1. Gastrointestinal
and pancreatic neuro-
endocrine cell types,
secretory products, and
associated neoplasms.
CCK, cholecystokinin; GIP,
gastric inhibitory peptide;
GLP-1, glucagon-like pep-
tide 1; NPY, neuropeptide
Y (tyrosine); PP, pancreatic
polypeptide; PYY, poly-
peptide YY (tyrosine, tyro-
sine). (Image courtesy of
Hauso et al.47)
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Secretion is regulated by G-protein coupled receptors
(GPCRs), ion-gated receptors, and receptors with tyrosine
kinase activity.61 An interactomic map of the known regu-
lators of secretion can be built to visualize this machinery,
providing an overview of the “secretome” (Figure 3).
Overall, secretory regulation includes tightly interrelated
inputs from stimulatory receptors, which activate signaling
pathways leading to exocytosis. The latter phenomenon is
characterized by well-deﬁned processes, including vesicular
amine uptake, vesicle formation, migration, and docking
with release of contents.
Individual neuroendocrine cell types may differ in terms
of signaling inputs, but the majority of pathways are
conserved. In some neuroendocrine cell types, such as
gastric G-cells, GPCRs activate protein kinase A (PKA) and
adenosine 30,50-cyclic monophosphate (cAMP) production
with downstream activation of the ERK1/2 (extracellular-
signal-regulated kinase 1/2: mitogen-activated protein ki-
nase, MAPK) pathways. In other types, such as gastric ECL
cells, the phosphoinositide-3 kinase/diacylglycerol/protein
kinase C (PI3K/DAG/PKC) pathways, and downstream, Ca
2þ
ﬂux regulation (either an internal inﬂux of calcium through
calcium channels, or IP3-mediated efﬂux of calcium into
the cytoplasm from endoplasmic stores) is activated.62Membrane depolarization, as in pancreatic b-cells, can also
ensue as ion-gated receptors are activated (eg, Sur/Kþ re-
ceptors or g-aminobutyric acid [GABA]-mediated Naþ/Kþ
channel activators) with calcium entry.63 These pathways
often involve mononucleotide signalers such as cyclic gua-
nosine 30,50-monophosphate. The latter cells call also be
hormonally regulated (incretins) via gastric inhibitory
peptide and glucagon-like peptide-1.64
Receptors with tyrosine kinase activity initiate PKC
pathway activation, leading to downstream effects that
include phosphorylation of multiple proteins involved in
granule maturation, migration, and docking to the mem-
brane.65 Cytokines and bacterial products may also affect
secretion, largely through nuclear factor kB (NFkB)
signaling pathways.46 Activation of these pathways is not
limited to secretion but may also activate transcription of
enzymes involved in amine production, such as cAMP-
mediated cAMP response element-binding protein
(CREB) transcriptional regulation of tryptophan hydroxy-
lase (TPH1, the rate-limiting enzyme in 5-HT synthesis)66
or PKC-mediated phosphorylation (and stabilization half-
life and thus activity) of this enzyme. Other pathways
such as MAPK are involved in transcriptional regulation of
HDC (histidine decarboxylase), the histamine biosynthetic
enzyme.
Figure 2. Mechanistic basis of secretory regulation in a neuroendocrine cell. Initial transcription and processing occurs in
the nucleus and endoplasmic reticulum (ER) and thereafter secretory products accumulate in the trans-Golgi network (TGN).
Subsequently, they are incorporated into immature vesicles that also contain other protein products destined for immature
secretory vesicles (ISG). Multiple ISGs fuse into a mature secretory granule (MSG) in a process that involves calcium (Ca2þ)
inﬂux, granule acidiﬁcation, and prohormone processing as well as amine uptake (eg, serotonin). This sequence of processes
is directed via positive regulatory inputs from diverse regulatory G-protein coupled receptors (GPCRs) (green). Ligand binding
activates both signal pathways (PKA/cAMP, MAPK, PI3K/DAG/PKC) and membrane depolarization. Regulatory GPCRs are
typically cell-type speciﬁc and include muscarinic, tastant, and trace amine receptors. Consequent upon activation MSGs are
directed to the plasma membrane, and, after receptor-mediated Ca2þ inﬂux, docking occurs at the cell membrane. This
process involves the expression of a series of proteins including syntaxin (SY), synaptotagmin (ST), vesicle-associated
membrane protein 2 (VAMP2) (V2), and synaptosomal-associated protein, 25-kDa (SNAP25) (S25) (green arrowheads). The
ensuing vesicle-and-membrane fusion process culminates in MSG release of contents into the extracellular milieu (exocy-
tosis). Inhibition of secretion occurs through a number of GPCRs (pink) (somatostatin > muscarinic > glutamate) which upon
activation reverses the signaling pathway initiation process through dephosphorylation of signaling intermediates as well as
inactivation of voltage-gated channels. Red dots ¼ secretory protein. IUPHAR gene symbols are included for each of the
GPCRs.
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nergic receptors (A2-A/B adenosine receptors, AdoR-A2A/
B),67 and interleukins (IL-1b/2). These responses (activa-
tion of transcription and secretion) are largely regulated by
Ca2þ inﬂux, PKA/cAMP, ERK1/2, and NFkB signaling path-
ways. Secretagogue-evoked stimulation induces actin reor-
ganization through sequential ordering of carrier proteins at
the interface between granules and the plasma membrane,
allowing for membrane trafﬁcking and culminating in
release of neuroendocrine contents.68
Secretory inhibition is prototypically initiated via
somatostatin (acting dominantly via the somatostatin 2
[sst2] receptor), acetylcholine (muscarinic M4 receptors, but
also can be stimulatory via M3 receptors), and g-amino-
butyric acid (GABA, via GABAA receptors).
69 Blockade of
secretion occurs through inhibition of pathways involved in
stimulating secretion. This includes inhibition of interme-
diate signaling such as cAMP (through dephosphorylation
of PKA) or PKC inactivation (dephosphorylation) with
reversals of Ca2þ inﬂux.70 The latter can also occur throughmembrane repolarization and inhibition of voltage-gated
L-channels.71
Mechanistic Basis of
Proliferative Regulation
Proliferative regulators of GEP-NEN are, for the most
part, poorly understood. The two best characterized and
described are gastrin and gastric ECL cells and transforming
growth factor-b (TGF-b) on the small bowel EC cell. Gastrin,
via the cholecystokinin 2 (CCK2) receptor, is the principal
regulator of ECL cell proliferation via a MAPK-activated
signal transduction cascade72 and induction of the acti-
vator protein-1 (AP-1) complex (a FOS/JUN-mer) transcrip-
tion factor.73 The latter regulate the genes necessary for cell
cycle progression (eg, cyclin genes).74 Physiologic ECL cell
proliferation is associated with fos/jun transcription activa-
tion by the MAPK pathway (ERK1/2) after gastrin-mediated
Ras activation.75 Such proliferation rarely, if ever, leads to
neoplastic progression and morphologic appearances of
Figure 3. Protein interactomes involved in neuroendocrine neoplasm secretion. Secretory regulation includes tightly
interrelated inputs from stimulatory receptors, including cholecystokinin, muscarinic, adenosine (AdoR-A), pituitary adenylate
cyclase-activating polypeptide (PACAP), and GABA receptors (stimulation). These activate signaling pathways (signaling)
including MAPK/PKC, PKA/cAMP/CREB, NFkb, and PI3K activity. Secretion is activated through well-deﬁned processes that
include vesicular amine uptake, vesicle formation, migration, docking, and exocytosis. Inhibition occurs at the level of signaling
and involves somatostatin—inhibition of protein kinase C—and the ionotropic glutamate receptor family (ligand-gated ion
channels and depolarization). Created with protein/transcripts identiﬁed in neuroendocrine neoplasms and String 9.1.213
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In some circumstances, a mutation or loss of function of
the menin gene represents an inherent “hit,” and hyper-
gastrinemia culminates in the development of type II gastric
carcinoids (Zollinger–Ellison syndrome/multiple endocrine
neoplasia type 1 [ZES/MEN-1]) with a classic neoplastic
(invasive/metastatic) phenotype.77 Under such conditions,
diffuse ECL cell proliferative changes are evident; at least
linear and micronodular hyperplasia are noted in>50%, and
invasive gastric carcinoids occur in w25%.78 Gastrin-
producing tumors (eg, gastrinomas) appear to be regulated
by insulin-like growth factor-I (IGF-I).79
The physiologic proliferative regulation of small intesti-
nal EC cells is largely unknown, but TGF-b1-mediated
growth inhibition appears a key component.80 TGF-b1 is a
potent stimulator of neoplastic EC cell proliferation and
functions to decrease expression of SMAD family member 4
(SMAD4) with concomitant increased expression of the in-
hibitor of SMAD nuclear translocation, SMAD7.80 TGF-b1
down-regulates P21WAF1/CIP1 transcription and increases
expression of c-Myc, resulting in phosphorylation and cross-
activation of the ERK1/2 signaling pathway. This culminates
in downstream activation of malignancy-deﬁning genes suchas MTA1 (metastasis associated 1). Once transformed into a
neoplastic phenotype, EC-derived-NEN are characterized by
a loss of responsiveness to TGF-b1.80
HER1 (EGFR, epidermal growth factor receptor) is
expressed in the majority (>80%) of small intestinal and
rectal NEN.81–83 At a molecular level, EGFR aneusomy
occurs in w20% of cases, and an elevated EGFR copy
number has been noted in w40%.84 The therapeutic rele-
vance of this pathway, however, remains unclear because it
is unknown whether the intracellular (and thus effector)
domain is expressed in GEP-NEN.85
In contrast with the delineation of the positive regula-
tors of NEN proliferation, the inhibitors have been well
characterized, particularly the analogs that target somato-
statin receptors. Somatostatin-receptor activation has been
linked to at least four different inhibitory effects.86 These
include 1) inhibition of adenyl cyclase, with a subsequent
decrease in intracellular cAMP resulting in down-regulation
of PKA; 2) activation of Kþ and Ca2þ channels, leading to
inhibition of transmembrane Ca2þ inﬂux and resulting in a
reduction of intracellular Ca2þ; 3) activation of protein
phosphatases (eg, calcineurin), which inhibit the exocytosis
and serine/threonine phosphatases that inﬂuence Ca2þ and
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phosphatases, which, through different pathways, inhibits
proliferation. Somatostatin has been noted in in vitro sys-
tems to affect the activity of phospholipase C, cyclic gua-
nosine 30,50-monophosphate, and phospholipase A2.
87
However, it remains unclear whether somatostatin is
directly antiproliferative or acts through inhibition of
growth factors and/or various trophic hormones such as
growth hormone, IGF-I, insulin, gastrin, or epidermal
growth factor from both the neoplastic cell and the sur-
rounding tumor matrix.88 Nevertheless, irrespective of the
mechanism, the clinical data provide some support for a
role for this biotherapy as a negative regulator of GEP-NEN
proliferation.28,29Intracellular Signaling Pathways
GEP-NEN exhibit three major signaling pathways: Ras/
Raf/MAPK, PKC, and PI3K/protein kinase B (Akt) with someFigure 4. Protein interactome involved in neuroendocrine ne
regulated signaling interactome (including RAS/RAF, MAPK, an
potential for pathway cross-activation and redundancy in signa
regulation of G1/S transition during the cell cycle. Known mu
reﬂective of the frequency of mutations (ie, MEN1/ATRX/DAXX m
These are largely peripherally localized (except for P27, regula
tumor-suppressor function. Targeting the somatostatin recepto
there is no direct link between these receptors and proliferative
interact with protein kinase C, this may provide a potential li
(MAPK) signaling. Current data renders it unlikely that somatost
inhibition. Created with protein/transcripts identiﬁed in neuroenparticipation of Notch signaling89,90 and Gli/Hedgehog/
SNAIL and Src kinases (Figure 4).91–93 The Ras/Raf/MAPK
and PKC pathways signal growth factor responses
(eg, tyrosine kinase receptor activators), typically from
stimulatory factors such as gastrin. PI3K/Akt regulates the
mammalian target of rapamycin (mTOR) complexes, which
are regarded as master switches regulating cell fate and are
considered to be principal regulators of cell proliferation
and angiogenesis.94 As an intracellular protein, mTOR plays
a central role in cell growth, protein synthesis, and auto-
phagy by integration of input from multiple upstream
pathways (insulin, growth factors [IGF-I/IGF-2]), and mito-
gens. In addition, mTOR also functions as a sensor of cellular
nutrient and energy levels as well as the redox status.94
Two key pathways, the MAPK and PI3K/Akt pathways,
are of considerable relevance in non-NEN lesions. They
often exhibit activating mutations, usually due to constitu-
tive activation of MAPK such as through gene-encoding
serine/threonine-protein kinase B-Raf (BRAF) mutationsoplasm proliferation. Proliferative signaling includes a tightly
d PI3K/Akt). The number and extent of linkages illustrates the
ling. CCND1 (cyclin D1) represents a nexus focus involved in
tations in the interactome are identiﬁed (red); the size being
utations occur in 40%–50%, mTORw15%, P27KIP1w10%).
tor of G1 progression), which is consistent with their known
r family has clinical utility as an antiproliferative strategy, but
signaling pathways. Because these somatostatin receptors
nk by indirect inhibition of mitogen-activated protein kinase
atin inhibitory effects are transduced via proliferative signaling
docrine neoplasms and String 9.1.213
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such as phosphatase and tensin homolog deleted on chro-
mosome 10 (PTEN) in the Akt pathway.95 There is also
signiﬁcant cross-talk between the MAPK and Akt pathways,
and activation or inhibition in one pathway may cause signal
alteration in a second pathway. This is reﬂected in the
inadvertent therapeutic consequence of drug resistance
consequent to overactivation of compensatory path-
ways.96,97 By contrast, although NEN themselves do not
express common growth regulatory pathway mutations in
MAPK and PI3K/Akt (discussed in the next section), they
exhibit abnormalities (altered expression levels) in both
pathways.
The RAS/RAF/MAPK signaling pathway is usually acti-
vated,98,99 and expression of the BRAF activator Rap1 as
well as B-Raf itself can be detected by immunohistochemical
analysis (75%).100 In intestinal NEN, mutations in KRAS
upstream of MAPK were identiﬁed in 3 of 102 neoplasms
(w3%).84 The relationship to signaling was not evaluated.
Evidence for mTOR signaling is provided by observations
that PTEN expression has been noted in carcinoids (low/
middle grade NEN) whereas neuroendocrine carcinomas
exhibited low or no PTEN activity (PTEN absent in
w50%).101 This is reﬂected by the observation that Akt is
phosphorylated (activated) in 76% of NEN.102 The mecha-
nisms leading to these alterations are unknown but prob-
ably reﬂect the chromosomal losses (usually chromosome
18q but also alterations in 10q and 14q, sites of PTEN and
Akt, respectively) that have been identiﬁed (60%–80%) in
NEN.1
In much the same way that the secretome can be visu-
alized, our current understanding of the NEN proliferome
recognizes that it comprises a tightly regulated signaling
interactome with signiﬁcant cross-linkages consistent with
the potential for pathway cross-activation and redundancy
in signaling (Figure 4). A particular nexus of the system is
provided by CCND1 (cyclin D1), which is involved in the
regulation of the G1/S transition during the cell cycle.
Known mutations in the interactome are largely peripher-
ally localized (except for P27, regulator of the G1 progres-
sion), which is consistent with their known tumor
suppressor function. Although targeting the somatostatin
receptor family has clinical utility as an antiproliferative
strategy, there is no direct link between these receptors and
proliferative signaling pathways. Because these receptors
interact with PKC, this may, however, provide a potential
link by indirect inhibition of MAPK signaling.
The Landscape of
Neoplastic Transformation
GEP-NEN appear to be derived from stem cell–derived
local tissue-speciﬁc neuroendocrine cells of the gastroin-
testinal tract and pancreas. The former evolve from a
committed precursor cell within intestinal crypts103 or in
the pancreatic ductal epithelium.104 Transcription factors
involved in regulating the neuroendocrine phenotype, such
as PAX genes and neurogenin 3 (NGN3), are not considered
to play a role in the evolution of NEN.The Knudson hypothesis, which is well accepted for non-
NEN disease, proposes that neoplasms arise as a result of an
acquired genomic instability and the subsequent evolution of
tumor cells with variable patterns of selected and back-
ground aberrations.105 These observations were based upon
a comparison of age-speciﬁc incidence curves between
inherited and noninherited cases of retinoblastoma. The
former exhibited an increased incidence by an amount
consistent with the advance of progression by one rate-
limiting step. This provided a method of analysis by which
quantitative comparisons of age-speciﬁc incidences between
two groups could be used to infer the underlying processes
of progression. Such a comparison identiﬁed a genetic mu-
tation as a key rate-limiting step. Proto-oncogenes (eg, genes
regulating cellular proliferation) increase the probability of
cancer when activated,106 but carcinogenesis generally re-
quires that mechanisms of DNA repair, such as tumor sup-
pressor genes, are also inactivated.105,107 Numerous
activating mutations (eg, BRAF V60E) have been identiﬁed
(see: http://cancer.sanger.ac.uk/cancergenome/projects/
cosmic/). Tumor-suppressor genes have also been identi-
ﬁed, but these are fewer in number. Modeling of cancer-gene
activation and studies of the evolution of cellular defense
mechanisms have determined that oncogenes may be
frequently activated ﬁrst within populations of large organ-
isms, with tumor-suppressor gene inactivation as a second
step before cellular deregulation and tumor emergence.108
This conforms to the classic cancer paradigm.
Unlike in the majority of cancers, activating mutations
are infrequent if not largely unknown in GEP-NEN
(Figure 5). Indeed, most neuroendocrine neoplasms of
the small and large intestines arise in a sporadic manner.
Others, notably ECL cell neoplasms of the stomach, are
associated with ECL cell hyperplasia, usually due to
hypergastrinemia. Gastrin-containing G-cell neoplasms and
somatostatin-secreting D-cell neoplasms of the duodenum
as well as pancreatic NEN are associated with MEN-
1–related neuroendocrine cell neoplasia.109 The latter may
not reﬂect transformation of islets and instead may be
derived from pluripotent cells in the ductal/acinar
system.110Pancreatic NEN Molecular Events
Apart from inherited neoplasms—those that exhibit
germ-line mutations in MEN-1 (discussed in detail in the
section Menin Mechanisms and Metastases)—little is known
of the molecular basis for oncogenesis or of the progression
of sporadic pancreatic NEN (the majority).111 Standard
mutations in k-ras, P53, myc, fos, jun, src, and the Rb gene
have not been speciﬁcally implicated.112,113 K-ras, para-
doxically, has been implicated in the suppression rather
than the promotion of pancreatic endocrine cells through
Ras association (Ral/GDS-AF-6) domain family member 1
(RASSF1A) and blockade of the RAS-activated proprolifer-
ative RAF/MAPK pathway by menin.114 Loss of heterozy-
gosity (LOH) at the MEN1 locus (eg, 11p13q) remains the
commonest alteration in pancreatic NEN, and whole exome
sequencing has not identiﬁed any novel gene activator
Figure 5. Inherited mutations have only been identiﬁed in tumor-suppressor genes (TSGs), and occur in <5% of all
gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). Although no activating mutations have been identiﬁed in
the molecular targets (eg, RAS or BRAF), the biologic results of TSG loss (chromatin and transcriptional alterations as well as
changes in cell cycle regulation) are a consequence of alterations signaled by these oncogenes. The second “hit” under these
conditions remains to be identiﬁed. Somatic alterations are more common and have been variably identiﬁed in 1%–50% of
GEP-NEN. These typically involve mutations, loss of heterozygosity (LOH), and chromosomal changes (eg, telomeric or in-
stabilities) that result in activated signaling pathways including RAS/RAF/MAPK, PI3K/Akt/mTOR, Src kinases, or histone
modiﬁcations. They exhibit similar biologic consequences as inherited mutations. The growth regulatory milieu and propro-
liferative signaling, such as through growth factors, likely contribute to tumor development. Molecular alterations at a DNA
level remain undeﬁned in w50% of tumors.
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genes—MEN1 (w50%), alpha thalassemia/mental retarda-
tion syndrome X-linked (ATRX, 18%), death-domain asso-
ciated protein (DAXX, 25%), and to a far lesser extent, mTOR
(15%)—have been identiﬁed.115 Gene knockout/knock-in
studies conﬁrm the relevance of MEN-1 whereby inactiva-
tion uncouples the endocrine cell cycle progression from
environmental cues such as glucose, leading to islet cell
proliferation.116 Both ATRX and DAXX (which both encode
proteins involved in chromatin remodeling) are somatically
mutated in w40% of pancreatic NEN and are associated
with activation of alternative lengthening of telomeres. In
addition, decreased expression (and, by inference, function)
is associated with chromosome instability and correlates
with tumor stage and metastasis, a reduced time of relapse-
free survival, and a decrease in survival.117 More recently, a
recurrent somatic mutation in YY1 (T372R) was noted in
w30% of sporadic insulinomas.118 YY1 is a member of the
GLI-Kruppel class of zinc ﬁnger transcriptional repressors
linked to mTOR signaling and histone modiﬁcation.119
Clinically, the T372R mutation is associated with a later
onset of tumors.118
Molecular and cytogenetic analyses have identiﬁed a
number of chromosomal alterations in pancreatic NEN.
Comparative genomic hybridization (CGH) studies indicate
chromosomal losses occur more frequently than gains, while
ampliﬁcations are uncommon.120,121 The total number of
genomic changes per tumor appears linked to tumor volume(size) and disease stage, indicating that genetic alterations
accumulate during the natural history of the lesion. Thus,
large neoplasms with increased malignant potential—and
especially metastases—tend to harbor more genetic alter-
ations than the small and clinically benign neoplasms. This
suggests that a loss of tumor-suppressor pathway(s) and
genomic instability represent mechanisms associated with
progression but not initiation of pancreatic NEN. Losses of
chromosomes 1 and 11q as well as gains on 9q are, how-
ever, early events because they have been identiﬁed in small
neoplasms. Prevalent chromosomal alterations common in
metastases include gains of both chromosome 4 and 7 and
losses of 21q, implying that these chromosome imbalances
may contribute to tumor metastasis.122,123 The relevant
genes (and pathways) have not yet been elucidated.
Deletions of 9p, which occur in w30% of pancreatic
NEN, include the P16INK4A and P14ARF genes, both of which
encode tumor suppressors; loss of this gene locus may lead
to tumorigenesis due to deregulation of the P53 and cyclin
D1/Rb pathways. Alterations in the cyclin D1 pathway in
pancreatic NEN indicate overexpression of this proto-
oncogene in 43% of neoplasms.124 Chromosome 16p,
which contains TSC2 (tuberous sclerosis complex 2
[tuberin], a tumor suppressor of the Akt/mTOR pathway
with GTPase-activating function), is lost in w40% of
pancreatic endocrine tumors,122,125 whereas PTEN a second
tumor suppressor at this locus, is lost in 10% to 29% of
lesions.122,125,126 Low expression of either TSC2 or PTEN
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functional” status, liver metastasis at diagnosis or follow-up
evaluation, and the proliferation index score and time to
progression.127 This supports involvement of the Akt/mTOR
pathway in pancreatic NEN tumorigenesis and progression.
Pancreatic NEN also overexpress the mouse double-minute
genes (now MDM oncogene, E3 ubiquitin protein ligase)
MDM2 and MDM4, and protein phosphatase 1D (PPM1D/
WIP1), all of which may attenuate the function of P53.
Because P53 is critical in maintaining genomic stability, al-
terations in regulators of P53 are considered to play a
permissive role in pancreatic NEN pathogenesis.128 One
report documents a 100% association of X-chromosome
deletions with pancreatic NEN.129 Two studies of pancreatic
NEN found no evidence of microsatellite instability
(MSI).130,131Small Intestinal NEN Molecular Events
DNA sequencing of small intestinal NEN failed to identify
mutations in MEN1, DAXX, or ATRX and identiﬁed small in-
testinal NEN as one of the most genomically stable cancers
thus far analyzed.132,133 Point mutations (single-nucleotide
variants, SNVs) were barely detectable at an average rate of
0.1 SNV per 106 nucleotides (range: 0–0.59).132 MSI, a
common feature of small intestinal adenocarcinomas,134 is
uncommon in small intestinal NEN.130,131,135 Eight percent of
small intestinal NEN exhibit small insertions or deletions that
can inactivate the cell-cycle inhibitor CDKN1B or P27KIP1.133
An evaluation of GEP-NEN identiﬁed that menin or P27-
negative neoplasms (as opposed to menin/P27-dual-posi-
tive) were associated with a high histologic grade, lymph
node metastasis, and a more advanced stage in foregut and
small intestinal NEN. P27 loss was signiﬁcantly associated
with a decreased survival and was an independent factor for
poor overall survival. P27 is implicated in the MEN4 syn-
drome,136 and it is transcriptionally regulated by menin,137
suggesting that the mechanistic basis for pancreatic NEN
and small intestinal NEN may be coupled at a molecular level.
Somatic SNVs have been identiﬁed in 197 genes with a
preponderance of cancer genes in small intestinal NEN,
including FGFR2, MEN1, HOOK3, EZH2, MLF1, CARD11,
VHL, NONO, FANCD2, and BRAF.132 Whether these SNVs
have functional implications or reﬂect noninformative, bio-
logically silent SNPs is unknown. The absence of canonical
cancer mutations is supported by a limited study that used
CancerCode to identify tumor-speciﬁc mutations.138
CGH has identiﬁed gains in chromosomes 17q and 19p
(57%) and in 19q and 4q (50%)139 as well as in 4p (43%), 5
(36%), and 20q (36%). Chromosomal losses were noted in
18q or 18p (43%), and 21% had full or partial loss of 9p.139
Of 14 neoplasms, six had a full gain of chromosome 4, of
which four samples also had a gain of chromosome 5. There
were four neoplasms with a gain of chromosome 4 along
with a partial or full trisomy of chromosome 14.139 In a
separate CGH study, losses in 18q22-qter (terminal end of
chromosome 18q) (67%) and 11q22–23 (33%) were the
most common genetic defects, although losses of 16q (22%)
and gains of 4p (22%) were also identiﬁed.140Because 18q and 11q chromosomal losses have the
highest frequency, they may reﬂect early events in small
intestinal NEN tumorigenesis. Losses on chromosome 16
and gain-of-function on chromosome 4 are later events in
tumor/carcinoid development. This is supported by a report
that aberrations in 16q and 4p tend to occur in metasta-
ses.141 Lollgen et al142 conﬁrmed that 18q deletions were
characteristic of midgut NEN; losses were detected in 88%.
These ﬁndings have been conﬁrmed in more recent
reports.143,144
One of the genes encoded on chromosome 18 (18q21) is
the tumor suppressor gene DCC (deleted in colorectal car-
cinoma). Loss of this gene, which has been linked to the
tumor suppressor NCAM (neural cell adhesion molecule on
11q145), is thought to play a role in carcinoid genesis.146 A
40-kb heterozygous deletion in chromosome 18q22.1 has
been suggested as a potential inherited factor, but the low
occurrence (w6%) makes it difﬁcult to appreciate the sig-
niﬁcance.147 A gain of chromosome 14 has been identiﬁed
as a marker of poor prognosis,143 whereas the antiapoptotic
protein DAD1 (defender against cell death) has been iden-
tiﬁed in one of the chromosome 14 foci, and conﬁrmed (via
immunohistochemistry) to be overexpressed.144
Another CGH study identiﬁed that w20% of small in-
testinal NEN exhibited alterations in the distal part of 11q
(location of succinate ubiquinone oxidoreductase subunit D
gene, SDHD).141 Furthermore, two of ﬁve small intestinal
NEN had a missense mutation in the SDHD gene in associ-
ation with LOH of the other allele, suggesting that alter-
ations in this gene may be implicated in tumorigenesis.141
An analysis of MSI in well-differentiated small intestinal
NEN or their metastases using the BAT-26 microsatellite
locus in intron 5 of hMSH2 and the BAT-II microsatellite
region of TGFbRII135 identiﬁed no evidence for mismatch
repair-related instability. In contrast, carcinomas of the
small intestine exhibit MSI in w20% of cases,148,149 sug-
gesting that NEN evolve differently than epithelial neoplasia
in this organ.135 The latter exhibited high frequencies of
activating BRAF/KRAS mutations, which are typically absent
in NEN.134
The Promised Land of
Transcriptional Proﬁling
Transcriptional proﬁling of both pancreatic and small
intestinal NEN has demonstrated that both are character-
ized by nonoverlapping expression of transcripts both be-
tween and within each tumor group (heterogeneity of
expression).
Pancreatic NEN
A study of nine core biopsies (normal pancreas,
pancreatitis, pancreatic adenocarcinoma, pancreatic adeno-
carcinoma metastases, and pancreatic NEN) identiﬁed
pancreatic NEN as expressing a series of genes including
ANG2 (overexpressed in 89%).150 In addition, islet amyloid
protein and calcitonin signaling were two pathways
expressed. An assessment of 24 pancreatic NEN (including
50% insulinomas) using U133A Affymetrix (Santa Clara, CA)
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benign and malignant. The latter overlapped with the World
Health Organization category of “well-differentiated endo-
crine carcinoma” and was characterized by an over-
expression of FEV, adenylate cyclase 2 (ADCY2), nuclear
receptor subfamily 4, group A, member 2 (NR4A2), and
growth arrest and DNA-damage-inducible b (GADD45b).151
Platelet-derived growth factor receptor (PDGFR) was also
expressed, and phosphorylation of PDGFR-b was observed
in 83% of all neoplasms. Signal pathway analysis identiﬁed
b-catenin, cadherin, and DNA damage as critical elements.
Seventy-two primary pancreatic NENs, seven matched me-
tastases, and 10 normal pancreatic samples were examined
using the 18.5 K human oligo microarray from the Ohio
State University Cancer Center.127 A plethora of transcript
alterations were identiﬁed, but focus was directed to the
PI3K/Akt/mTOR pathway. TSC2 and PTEN were down-
regulated in most (w80%) of the primary tumors, and
this decreased expression was associated with shorter
disease-free and overall survival. In addition, they identiﬁed
that transcript levels of somatostatin receptor 2 (sst2) were
absent or low, particularly in insulinomas versus nonfunc-
tioning neoplasia, and that expression of ﬁbroblast growth
factor 13 (FGF13) was associated with liver metastasis and
shorter disease-free survival.120 In addition, signaling
abnormalities were noted in catenin/cadherin pathways as
well as in Akt signaling, while recessive disease-associations
included PI3KR1 and RB1 in pancreatic NEN.Small Intestine
Affymetrix transcriptional proﬁling identiﬁed >1,500
overexpressed and w400 transcripts that are decreased in
expression in a group (w30 samples) of small intestinal
NEN.152 Further analysis identiﬁed three potentially useful
malignancy-marker genes. Speciﬁcally, overexpression of
nucleosome assembly protein-like 1 (NAP1L1), melanoma-
associated antigen D2 (MAGE-D2), and MTA1 mRNA and
MTA1 protein in tumor and metastatic small intestinal NEN
was conﬁrmed. These genes may be markers for identifying
metastatic tumors, and NAP1L1 may be a neuroendocrine
tumor-speciﬁc marker.152 Overexpression of MTA1 has been
conﬁrmed,153 and expression of these markers is effective in
the prediction of small intestinal NEN grade and stage.154
Other candidate marker genes have been identiﬁed in
small intestinal carcinomas,155 including paraneoplastic
antigen Ma2 (PNMA2), testican-1 precursor (SPOCK1),
serpin A10 (SERPINA10), glutamate receptor ionotropic
AMPA 2 (GRIA2), G protein-coupled receptor 112 (GPR112),
and olfactory receptor family 51 subfamily E member 1
(OR51E1). Further assessment of PNMA2 identiﬁed elevated
protein levels, particularly in the blood, and titers were
sensitive, speciﬁc, and superior to CgA measurement for the
risk of recurrence after small intestinal NEN resection.156
A separate gene expression study identiﬁed that primary
tumors and lymph node metastases in 19 patients differed
in expression proﬁles, suggesting evidence for genetic
change during metastasis.157 Genes identiﬁed in neoplastic
progression included actin g2 (ACTG2), gremlin 2 (GREM2),regenerating islet-derived protein 3a (REG3A), tumor sup-
pressor candidate 2 (TUSC2), runt-related transcription
factor 1 (RUNX1), tryptophan hydroxylase 1 (TPH1), trans-
forming growth factor-b receptor, type II (TGFBR2), and
cadherin 6 (CDH6). The functional role of TGFbRII has been
conﬁrmed in NEN.135
Small intestinal NEN also exhibit a distinctive gene
expression proﬁle compared with pancreatic neoplasia, and
transcriptional proﬁling has also identiﬁed up-regulation of
extracellular matrix protein 1 (ECM), VMAT1, galectin 4
(LGALS4), and RET proto-oncogene (RET).151 A reanalysis of
two publicly available small intestinal tumor transcriptomes
(Yale and Uppsala) using network-based approaches iden-
tiﬁed the existence of two potentially different small intes-
tinal NEN types: one group that principally synthesizes and
secretes 5-HT and a second that expresses serotonin, sub-
stance P, and other tachykinins.158 The integrated cellular
transcriptomic analyses conﬁrmed the expression of core
secretory regulatory elements such as carboxypeptidase E
(CPE), proprotein convertase subtilisin/kexin type 1
(PCSK1), secretogranins, including genes involved in depo-
larization such as neuronal speciﬁc protein channel 3
(SCN3A), and transcription factors associated with neuro-
development (NKX2-2, NeuroD1, INSM1) and glucose
homeostasis (amyloid b [A4] precursor-like protein 1,
APLP1). These neoplasia were regulated at a developmental
level, and they expressed activation of hypoxic pathways
(a known regulator of malignant stem cell phenotypes) and
genes involved in apoptosis and proliferation. Further ana-
lyses (genomewide coexpression) identiﬁed that the small
intestinal NEN gene network was nonrandom, scale free,
and highly modular. Based on the mathematical apprecia-
tion of these parameters, it was inferred that the biologically
informative organizing principles could be assessed.159 The
superimposition of functional analysis conﬁrmed that pro-
cesses including nervous system development, immune
response, and cell cycle were expressed in the network. In
addition, it was apparent that substantial overexpression of
GPCR signaling regulators was evident. The signiﬁcance of
the expression of neural GPCRs is their key role in the dif-
ferential activation of CRE targets associated with prolifer-
ation and secretion.
Global micro-RNA (miR) proﬁles of pancreatic and
small intestinal NEN reveal nonoverlapping expression of
regulators both between and within each NEN type, similar
to transcriptome analysis.160–163 In pancreatic NEN, up-
regulation of miR-103 and miR-107 was identiﬁed,160
and miR-21 overexpression was associated with both
high proliferation and liver metastases.160 In contrast, a
separate study reported that expression of miR-642
correlated with proliferation, and miR-210 was associ-
ated with metastatic disease.161 Li et al162 independently
noted that down-regulation of serum miR-1290 discrimi-
nated pancreatic NEN from adenocarcinomas. In small
intestinal NEN, ﬁve miRNA including miR-96, miR-182,
miR-183, miR-196, and miR-200 were up-regulated during
tumor progression, whereas four (miR-31, miR-129–5p,
miR-133a, and miR-215) were signiﬁcantly down-regu-
lated.163 The cardiac-speciﬁc miRNA-133a has been
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relevance of this observation remains to be determined. It
is likely that network-based approaches may have more
utility for identifying relevant miRNAs as well as deter-
mining biologically useful interactions that have potential
clinical relevance.Menin Mechanisms and Metastases
Pancreatic NEN
Pancreatic NEN are typically more aggressive than other
GEP-NEN. This likely reﬂects the mutational spectrum:
MEN-1, ATRX, and DAXX are identiﬁed in w50% of lesions.
It is noteworthy that all the genes linked to inherited syn-
dromes in pancreatic NEN are tumor-suppressor genes;
none are oncogenes. The single gene conﬁrmed as mutated
in small intestinal NEN (<10%), P27KIP1, is also a tumor-
suppressor gene. To date, no inherited genetic factors are
known; however, sporadic reports of familial relationships
suggest that genetic factors remain to be identiﬁed.165
The MEN1 gene is located on the long arm of chromo-
some 11, band q13.166 Tumorigenesis likely involves loss of
function of this growth-suppressor gene,105 and it is
considered to follow a two-step process: a germline muta-
tion affecting the ﬁrst MEN1 allele, and a second somatic
inactivation of the unaffected allele (LOH). Menin, a
610-amino acid nuclear protein encoded by the MEN1 gene,
interacts with Jun D and the activator protein-1 (AP-1)
transcription factors to modify growth-regulatory signaling.
It also networks with nm23H1/nucleoside diphosphate
kinase (nm23), and exerts GTPase activity.167 This gene
product is also linked to TGFb signaling (through
SMADs),168 RAS-RAF signaling,114 and Gli1/hedgehog
signaling169 as well as to histone modiﬁcation (with tran-
scriptional regulation of a plethora of genes).170 Its associ-
ation with a histone methyltransferase complex containing,
MLL2 results in differential methylation of histone H3 on
lysine 4, and its association with RNA polymerase II is
linked to the regulation of Hox expression.171
Menin likely functions as a neuroendocrine nexus gene
(a master regulator)172 that controls cell signaling as well
as gene expression, including differentiation-regulating
genes in pancreatic NEN. As a classic tumor suppressor, a
second hit is required for tumorigenesis (often considered
as LOH). As previously noted, an inherited MEN-1 mutation
results in pancreatic NEN and the development of gastric
carcinoids, particularly if trophic hormones such as gastrin
are elevated (eg, in Zollinger-Ellison syndrome). It is enig-
matic that the same inherited mutation is not associated
with the synchronous development of neuroendocrine
neoplasia in the small intestine or other gut sites. The
mechanisms that regulate the penetrance of the MEN1 gene
are unknown.
Three other inherited NEN gene disorders include those
of the von Hippel-Lindau tumor suppressor (VHL), nuclear
factor 1 (NF-1), and the tuberous sclerosis complex (TSC)
family. VHL173 interacts with the elongin family of proteins
to regulate transcriptional elongation174 and may play a role
in hypoxia-induced cell regulation and extracellular matrixﬁbronectin expression and localization.175 Mutations in
NF-1 result in down-regulation of the P21ras signaling
pathway, which leads to a constitutively activated guanosine
triphosphate (GTP) (similar to menin) culminating in
abnormal cell proliferation.176 The TSC genes, hamartin
(TSC1), and tuberin (TSC2), play a role in the PI3K/Akt
pathway, in cell adhesion (glycogen synthase kinase 3
pathway), and in proliferation (MAPK pathway).177
Small Intestinal NEN
An inherited disposition for small intestinal NEN has yet
to be published; however, families who have multiple kin-
dreds with the disease (eg, see http://clinicaltrials.gov/
show/NCT00646022) have been identiﬁed, and candidate
genes are being sought. Genetic analyses of a family with
three consecutive ﬁrst-degree relatives failed to identify an
inherited MEN-1 predisposition.165 Similar studies,178,179
indicate that the menin gene is not linked to inherited tu-
mors of the small intestine.
Additional support for an inherited factor has been
provided by family cancer studies. The Swedish Family
Cancer database study identiﬁed an increased risk of small
intestinal NEN in the progeny of patients with squamous
cell skin cancer (relative risk 1.79), non-Hodgkin lym-
phoma (relative risk 2.06), and endometrial cancer (rela-
tive risk 2.21).180 The children of patients with small
intestinal NEN had an increased risk of cancer of the breast
(relative risk 1.39), kidney (relative risk 2.08), and brain
(relative risk 1.65). This and other epidemiologic-based
studies180,181 have suggested that an increased risk of
developing small intestinal NEN occurs in individuals who
have a parental history of the disease, and that a family
history of any cancer (ie, not only NEN) is a risk factor for
the development of these neoplasia.182 The mutations
linked to small intestinal NEN disease development remain
unknown.
Metastases
NEN metastatic disease remains a conundrum, despite
the fact that the majority of GEP-NEN have distant spread
when diagnosed.1 It is unclear why in the almost complete
absence of known cancer-causing mutations as well as the
relatively low proliferative potential of tumors (>60% small
intestinal NEN are low grade [<2% proliferating index]),
most tumors are metastatic. Evidence for this is based on a
series of epidemiologic studies. Typically, 12% of GEP-NEN
<10 mm have already metastasized at the time of diagnosis,
and 60% of lesions <20 mm are metastatic.8 This is
particularly relevant for small intestinal and colonic NEN,
wherew90% were already metastatic at 20 mm in size. It is
noteworthy that 72% of small intestinal NEN are already
metastatic when the primary is only 10 mm in size.8 Thus,
metastasis occurs despite “indolence” and is not reﬂected in
survival (there is no statistically signiﬁcant difference in
survival between localized and metastatic disease with
small intestinal NEN: 94% and 80%, respectively).8 The
long-accepted adage that there is a direct relationship be-
tween size and the development of metastases thus does not
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nisms that drive metastasis (like those that drive tumori-
genesis) remain ill-deﬁned; however, two genes, ATM and
MTA1, have been implicated.
Ataxia telangiectasia mutated kinase (ATM) gene. The
ataxia telangiectasia mutated kinase (ATM) gene is the causal
gene of Ataxia-telangiectasia and is involved in the regulation
of DNA damage responses; hyperactivation of ATM is asso-
ciated with increased metastasis through overexpression of
epithelial-mesenchymal markers like SNAIL.183 A study of
colorectal NEN (n ¼ 31) using polymerase chain reaction
arrays noted that high ATM mRNA levels were strongly
correlated with overexpression of ATM protein by immuno-
histochemistry and low-proliferation rates.184 ATM-
negativity was also associated with signiﬁcantly decreased
overall survival. This was conﬁrmed both in an independent
validation set (20 metastatic and 18 non-metastatic GEP-
NEN, including pancreas and rectum) where a decreased
ATM transcript were associated with metastasis. In a subse-
quent pancreatic NEN study (n ¼ 107), high ATM expression
was associated with a signiﬁcantly smaller tumor size, lower
recurrence rate, and well-differentiated tumors.185 Overall,
ATM down-regulation was associated with metastases184; the
mechanism, however, appears to differ from non-
neuroendocrine neoplasia such as breast cancer, where hy-
peractivity not loss of activity is mechanistically linked to
metastasis.183
Metastasis-associated 1 gene (MTA1). Metastasis-
associated 1 gene (MTA1) is an important component of the
nucleosome remodeling and histone deacetylase (NuRD)
complex, and it plays a role in DNA repair, inﬂammation,
and pathogen-driven pathologic conditions.186 MTA1 was
initially identiﬁed by transcriptional proﬁling to be over-
expressed in small intestinal NEN,152 and subsequent
functional studies identiﬁed up-regulation by TGF-b
which also induced gene responses associated with growth
promotion (c-Myc and the ERK pathway) and invasion
(E-cadherin).80 MTA1 has more recently been reported as
overexpressed in the majority (>95%) of small intestinal
NEN, suggesting that this gene may activate the molecular
pathway(s) promoting tumor progression and metastasis
development.187 Mathematical modeling demonstrates that
tumor expression levels (mRNA) of MTA1 can be used to
predict metastases with 100% sensitivity and speciﬁcity.154
Clinical Utility
The application of molecular information about NEN to
provide added clinical utility in GEP-NEN treatment can be
applied to three areas: functional imaging, the application of
transcriptomic technologies to diagnosis, and the identiﬁ-
cation of drug targets.
Identiﬁcation of Functional Imaging Targets
Imaging has a central role in the diagnosis, staging,
treatment selection, and follow-up evaluation of GEP-NEN.
In this respect, nuclear medicine or functional techniques,
particularly positron emission tomography (PET), exhibit
optimal diagnostic sensitivity for these lesions.1 They areusually combined with a fusion of anatomic techniques to
maximize the acquisition of clinically relevant spatial
information.188
The utility of these approaches is mostly based on tar-
geting somatostatin receptors (>80% of lesions189,190) and
through leveraging the canonical amine precursor uptake
and decarboxylation (APUD) features of these lesions.
Nuclear medicine imaging consists of conventional scintig-
raphy typically undertaken with somatostatin analogs
(SSA) such as 111In-pentetreotide (or OctreoScan), or
99mTc-labeled analogues such as 99mTc-HYNIC-TOC) and
PET/computed tomography. PET techniques mainly use
68Ga-DOTA-SSA peptides (DOTA-NOC, -TOC, and -TATE).
Alternative PET techniques employ amine precursors such
as 18F-DOPA and 11C-5-hydroxytryptophan.191
The utility of this approach is based on one of the
fundamental properties of peptide-secreting neuroendo-
crine cells initially identiﬁed by Pearse in 1966.192 In
principle, this embodies active amino acid uptake (via large
amino acid transporters [LATs]193) as well as amine
transportation across the vesicular membrane, which is
undertaken by transporters that are proton-coupled anti-
porters.194 This coupling of intracellular transport with
vesicular accumulation forms the basis for tracer accumu-
lation and imaging (eg, 11C-5-HTP, 18F-DOP, and 123I-MIBG)
of neoplastic cells.193,195 Identiﬁcation of novel trans-
porters and metabolic molecules will lead to the develop-
ment of additional strategies for deﬁning tumor function.
Radiolabeled SSAs are mostly used because of their
theranostic properties, namely, the capacity of the same
receptor peptide of being used for imaging or therapy by
simply switching the radioisotope.196–198 It seems probable
that by using a molecular-based search strategy other
G-protein receptor peptides will be identiﬁed for clinical
study. In addition, the recognition of pathways that can be
imaged such as has been undertaken with increased glucose
metabolism, expressed as 18F-FDG uptake, can be used to
deﬁne the prognosis199 (Figure 6).Identiﬁcation of Drug Targets
Current molecular approaches have failed to identify
uniformly expressed novel, targetable DNA sequences in
NEN. Although a role for the mTOR pathway has been
suggested, mutations in only a small proportion of NEN
(w15% pancreatic NEN) suggest this may be a limited
target. It remains unclear in what settings mTOR inhibitors
would work.200 It does, however, raise the possibility of
menin as a candidate target. Menin is the most commonly
altered gene locus in GEP-NEN (w50% of pancreatic NEN as
well as gastric carcinoids) and its interaction with P27
signaling (mutated in small intestinal NEN) suggests it may
provide a common target that encompasses both tumor
types.
Because the menin crystal structure is available, prog-
ress has been made in the development of potent small-
molecule and peptidomimetic inhibitors of the gene
product.201 However, the majority of studies have focused
on the role of menin as an essential cofactor in oncogenic
Figure 6. Functional imaging of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) using radiolabeled li-
gands. Radiolabeled somatostatin analogs (SSAs) are the most exploited. Scintigraphy with 111In-pentretreotide and, more
recently, positron emission tomography (PET)/computed tomography techniques with 68Ga-SSA target somatostatin re-
ceptors (SSR) are regarded as the optimal nuclear medicine NEN imaging tools. Alternative PET techniques with amine
precursors such as 18F-DOPA and 11C-5HTP have also been shown to be sensitive modalities. Experimental techniques
include the use of SSR antagonists, GLP-1, GRP, and NK ligands. BOMB, bombesin; 11C-5HTP, 11C-hydroxy-tryptophan;
18FDG, 18F-ﬂuoro-2-deoxyglucose; 18F-DOPA, 18F-fFuoro-LL-DOPA; 68Ga-SSA: 68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-
DOTATATE; 68Ga-SS-ANT, 68Ga-labeled SSR antagonists; GLP-1, glucagon-like peptide-1 receptor; GLUT-1,3, glucose
transporter type 1 and 3; GRP, gastrin-releasing peptide receptor; 111In-SSA: 111In-Pentetreotide, 111In-Depreotide, 99mTc-
EDDA-HYNIC-Tyr3-octreotide; LAT 1,2, large neutral amino acid transporter type 1 and 2; NK1, neurokinin 1 receptor; SSR,
somatostatin receptor.
March 2015 Decoding the Pathobiology of GEP-NENs 145mixed-lineage leukemia (MLL) fusion proteins and the
development of targets to treat acute leukemia. Menin-
targeting drugs are challenging chemical problems, given
the difﬁculties in elucidating the mechanism by which
menin binds to protein effectors and given its complex
bivalent mode of engagement.202 Although there is the
rationale for targeting this gene and its pathways, clinical
utility will require the design of next generation of in-
hibitors for effective targeting in GEP-NEN.
The TGF-b pathway is also linked to menin (TGF-b/
SMAD signaling is altered inw25% of small intestinal NEN),
and targeting this area may provide an alternative approach.
Several agents (eg, SD-208 [2-(5-chloro-2-ﬂuorophenyl)-4-
[(4-pyridyl)amino]p-teridine]) have been developed that
target receptor kinase activity and limit tumor invasion and
metastasis in pancreatic adenocarcinoma and melanoma
models.203 Because no clinical data are currently available,
it remains to be seen whether they could be effective in
GEP-NEN.Translational Transcriptomics and
Network Neologies
Tumor transcriptomes contain information of critical
value to understanding the different capacities of a cell at
both a physiologic and pathologic level. In terms of clinical
relevance, they provide information regarding the cellular
toolkit—the pathways associated with malignancy and
metastasis or drug dependency. Exploration of this resource
thus can be leveraged as a translational tool to better
manage and assess neoplastic behavior.
Multiple genes or gene products have been identiﬁed
that could provide therapeutic targets (eg, FEV or MTA1)
to be used as biomarker measurements or to assess tumor
biology or identify new targets (network-targeted
approach).204,205 Gene-expression proﬁling and supervised
machine learning of marker panels of implicated in tumor-
igenicity, metastasis, and hormone production have suc-
cessfully been used to classify small intestinal NEN subtypes
and can accurately (100%) predict metastasis.154
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testing than tissue, a polymerase chain reaction approach
has been used to identify circulating NEN markers. Circu-
lating tumor mRNA can be detected in plasma, and a com-
bination of expression and measurements of circulating
NEN-related hormones and growth factors has provided
high sensitivity and speciﬁcity to diagnose small intestinal
NEN (81.2% and 100%, respectively).206 The NETest (Wren
Laboratories, Branford, CT), a more recent multianalyte
algorithmic analysis, includes 51 marker genes, exhibits
high sensitivity (>95%) and speciﬁcity (>95%) for the
detection of GEP-NEN, and provides a multidimensional
(gene cluster analysis) assessment of disease status.207,208
Multianalyte algorithmic analysis strategies of this type
are signiﬁcantly more accurate than CgA and pan-
creastatin209–212 and are not affected by proton pump
inhibitor usage.212Conclusion
GEP-NEN represent a diverse group of neoplasia that
exhibit a unique pathobiology and a neoplastic molecular
proﬁle that is substantially different from other epithelial
cancers. Traditional DNA sequencing approaches to inves-
tigating the molecular basis of NEN disease have, to date,
yielded relatively little information (with the exception of
pancreatic NEN). Consequently, one important question is to
characterize what constitutes the driver of neoplastic
development. This may involve a focus on noncoding or
long-chain RNA, a better delineation of the epigenome (and
how it is regulated), or an identiﬁcation of the environ-
mental trigger that leads to a neoplasia in a tumor-
suppressor milieu. It is likely that transcriptomics and
network analyses, especially if interfaced with proteomic
analysis, can help in further deﬁning the neuroendocrine
cellular toolkit. This strategy will contribute to resolving the
oncologic conundrum of GEP-NEN as well as facilitating
accurate molecular delineation of NEN disease.
With this approach in mind, a complete description of
the master regulators and nexus genes is required to
deﬁne what regulates metastasis and to identify candidate
drug targets based ﬁrmly on the pathobiologic rationale of
neuroendocrine neoplasia. Of particular relevance is the
need to deﬁne the regulator changes that occur as the
primary tumor evolves into a metastatic phenotype and in
so doing undergoes alteration in its spectrum of master
regulators and druggable targets. A further important
issue is to deﬁne accurate reporter systems that can pre-
dict and measure the efﬁcacy of drug therapies. Because
repetitive biopsy of metastases is not a viable clinical
option, the development of blood-based strategies to
measure and assess changes in the circulating molecular
signature are of critical relevance to both management
strategy and outcome analysis. The acquisition of answers
to these critical questions will be of clinical utility for the
development of novel imaging, multianalyte algorithmic
analyte biomarkers, and the advance of NEN-speciﬁc
therapeutic strategies.References
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